AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The Call for Abstracts remains open through 9 May 2025, offering a critical opportunity for professionals in the lysosomal disease field to contribute to the Summit’s scientific programme. Accepted abstracts will be considered for oral or poster presentations, with select oral presenters receiving a discounted registration rate. A limited number of scholarships are also available to support participation.
“Innovation begins with connection,” said Professor Maria Fuller, BAppSc, MAppSc, PhD, FFSc(RCPA), a 2025 Lysosomal Disease Summit Course Director. “This year’s Summit will bring together pioneering minds to explore cutting-edge research and ignite collaborations that shape the future of lysosomal diseases. Every contribution helps drive discovery forward and creates opportunities to meaningfully improve patient care.”
Programme Highlights
• Groundbreaking research presentations from international and APAC-based experts
• Strategic panel discussions on current challenges and treatment developments
• Dedicated sessions to support early-career researchers
• Networking and collaboration opportunities with global and regional stakeholders
Attendees will engage with leading voices in lysosomal disease research and treatment, explore diagnostic innovations, and build new partnerships across industry, academia, and clinical care.
For full details on abstract submissions, registration, sponsorship, and Summit updates, visit lysosomaldiseasesummit.org.
About the Lysosomal Disease Summit
The Lysosomal Disease Summit, a collaborative effort with Fabry Australia and independently managed by Etherio, is a premier scientific event dedicated to advancing research, collaboration, and innovation in lysosomal disease treatment. Now in its third year, the Summit serves as a vital forum for experts across the APAC region to share knowledge and drive progress in the field.
Sarah Jansen
Etherio
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
